STF-118804
NAMPT inhibitor / Potent and selective next generation inhibitor of nicotinamide phosphoribosyl transferase (NAMPT), inhibiting NAD+ biosynthesis from nicotinamide.1 It reduced the viability of most B-ALL cells with high potency (low nM range), eliminates leukemia stem cells from mouse bone marrow, and induces regression of ALL xenografts.1 It induces apoptosis and reduced neuroblastoma stem cell neurosphere formation in high-risk neuroblastoma cell lines.2 STF-118804 reduces the growth of pancreatic ductal adenocarcinoma cells.3
Biochemicals & reagents
894187-61-2
1 Matheny et al. (2013), Next-generation NAMPT inhibitors identified by sequential high-throughput phenotypic chemical and functional genomic screens; Chem. Biol. 20 1352 2 Vallejo et al. (2020), NAMPT Inhibition induces Neuroblastoma Cell Death and Blocks Tumor Growth; Front. Oncol. 12 883318 3 Espindola-Netto et al. (2017), Preclinical efficacy of the novel competitive NAMPT inhibitor STF-118804 in pancreatic cancer; Oncotarget 8 85054
-20°C
TARGET: Energy production -- PATHWAY: NAD, NADP pathways; AMPK pathway; mTOR -- RESEARCH AREA: Epigenetics -- DISEASE AREA: Cancer